Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Contrast Media Mol Imaging. 2018 Jul 30;2018:4198673. doi: 10.1155/2018/4198673. eCollection 2018.
We aimed at comparing the Durie-Salmon Plus (DS Plus) staging system based on Italian Myeloma criteria for PET USe (IMPeTUs) with other two staging systems in predicting prognosis of patients with all stages of newly diagnosed multiple myeloma (MM). A total of 33 MM patients were enrolled in this retrospective study. The variation between the DS Plus classification and Durie-Salmon staging system (DSS) or Revised International Staging System (RISS) classification was assessed. When staged by the DSS, patients in stage I and stage II did not reach the median overall survival (OS), and the median OS was 33 months for stage III (=0.3621). When staged by the DS Plus, patients in stage I did not reach the median OS of stage I, and the median OS for stages II and III was 38 and nine months, respectively (=0.0064). When staged by the RISS, patients in stage I did not reach the median OS, and the median OS was 33 and 16 months for stage II and stage III, respectively (=0.0319). The concordances between two staging systems were 0.07 (DS Plus versus DSS) and 0.37 (DS Plus versus RISS), respectively. Multivariate analysis revealed that DS Plus stage III (HR: 11.539, =0.021) and the Deauville score of bone marrow ≥4 (HR: 3.487, =0.031) were independent prognostic factors associated with OS. Both the DS Plus based on IMPeTUs and RISS possessed a better potential in characterizing and stratifying MM patients compared with the DSS. Moreover, DS Plus stage III and the Deauville score of bone marrow ≥4 were reliable prognostic factors in newly diagnosed MM patients.
我们旨在比较基于意大利多发性骨髓瘤 PET USe 标准的 Durie-Salmon Plus（DS Plus）分期系统（IMPeTUs）与其他两种分期系统在预测所有分期新诊断多发性骨髓瘤（MM）患者预后方面的差异。本回顾性研究共纳入 33 例 MM 患者。评估了 DS Plus 分类与 Durie-Salmon 分期系统（DSS）或修订国际分期系统（RISS）分类之间的差异。按照 DSS 分期，I 期和 II 期患者未达到中位总生存期（OS），III 期患者的中位 OS 为 33 个月（=0.3621）。按照 DS Plus 分期，I 期患者未达到 I 期的中位 OS，II 期和 III 期患者的中位 OS 分别为 38 个月和 9 个月（=0.0064）。按照 RISS 分期，I 期患者未达到中位 OS，II 期和 III 期患者的中位 OS 分别为 33 个月和 16 个月（=0.0319）。两种分期系统之间的一致性分别为 0.07（DS Plus 与 DSS）和 0.37（DS Plus 与 RISS）。多变量分析显示，DS Plus III 期（HR：11.539，=0.021）和骨髓 Deauville 评分≥4（HR：3.487，=0.031）是与 OS 相关的独立预后因素。与 DSS 相比，基于 IMPeTUs 的 DS Plus 和 RISS 均具有更好的特征和分层 MM 患者的潜力。此外，DS Plus III 期和骨髓 Deauville 评分≥4 是新诊断 MM 患者可靠的预后因素。
